On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials.
Therapeutic potential of CD20 x CD3 bispecific antibodies
- Post author:
- Post published:April 5, 2024
- Post category:uncategorized